Table 1.
Baseline clinical characteristics of patients.
| Transdermal MHT (n = 75) | Oral MHT (n = 293) | P value | |
|---|---|---|---|
| Age (years) | 54.3 ± 3.4 | 53.7 ± 3.4 | 0.201 |
| Parity (n) | 1.8 ± 0.8 | 1.8 ± 0.7 | 0.738 |
| Age at menarche (years) | 13.6 ± 1.4 | 13.7 ± 1.5 | 0.680 |
| Age at menopause (years) | 49.2 ± 3.4 | 49.4 ± 3.7 | 0.794 |
| Years since menopause | 5.1 ± 4.1 | 4.4 ± 4.1 | 0.202 |
| Body mass index (kg/m2) | 22.5 ± 3.0 | 22.2 ± 2.8 | 0.475 |
| Waist circumference (cm) | 74.2 ± 7.2 | 74.5 ± 7.1 | 0.778 |
| Systolic blood pressure (mmHg) | 114.8 ± 14.6 | 112.6 ± 14.8 | 0.303 |
| Diastolic blood pressure (mmHg) | 70.3 ± 10.0 | 68.9 ± 10.8 | 0.366 |
| Hypertension (%) | 12.0 | 7.8 | 0.255 |
| Type II Diabetes mellitus (%) | 4.0 | 2.7 | 0.703 |
| Dyslipidemia (%) | 24.0 | 15.0 | 0.064 |
| Current smoking (%) | 2.7 | 2.4 | 1.000 |
Data are presented as mean ± standard deviation or percent. P value based on t test or chi-square test, as indicated.
MHT menopausal hormone therapy.